|
1 |
Toward identification of personalized immunological profiles in multiple sclerosis
Hohlfeld, Reinhard. - Ludwig-Maximilians-Universität München, 2022
|
|
|
2 |
Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair
Enthalten in Neurotherapeutics 14.3.2022: 1-11
|
|
|
|
3 |
CD20+ T Cells as Pathogenic Players and Therapeutic Targets in MS
Meinl, Edgar. - Ludwig-Maximilians-Universität München, 2021
|
|
|
|
4 |
Charakterisierung von T-Zellen und T-Zell-Rezeptoren bei entzündlichen neurologischen Erkrankungen
Amft, Michaela. - München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2021
|
|
|
|
5 |
Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal
Thompson, Alan J.. - Ludwig-Maximilians-Universität München, 2021
|
|
|
|
6 |
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary
Hohlfeld, Reinhard. - Ludwig-Maximilians-Universität München, 2021
|
|
|
|
7 |
Features of MOG required for recognition by patients with MOG antibody-associated disorders
Macrini, Caterina. - Ludwig-Maximilians-Universität München, 2021
|
|
|
|
8 |
Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies
Mortazavi, Matin. - Ludwig-Maximilians-Universität München, 2021
|
|
|
|
9 |
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
Kappos, Ludwig. - Ludwig-Maximilians-Universität München, 2021
|
|
|
|
10 |
Tissue-resident CD8+ memory T cells in multiple sclerosis
Hohlfeld, Reinhard. - Ludwig-Maximilians-Universität München, 2021
|
|
Administration
